Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05155046 · ClinicalTrials.gov registry record · Phase 2
18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
A Phase 2 study of Localized Prostate Cancer, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
- 1
- Study location
NCT05155046 is a Phase 2 study of Localized Prostate Cancer that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 130 participants, above the 96-participant average among 6 other Localized Prostate Cancer trials with a reported enrollment target (35% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05155046, a Phase 2 study of Localized Prostate Cancer, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Identifying medium- and high-risk prostate cancer early may allow for treatments to work. But identification can be hard. Researchers want to see if a radiotracer used during PET scans can help. Objective: To test how an imaging agent called 18F-DCFPyL detects response to standard prostate cancer treatment. Eligibility: People ages 18 and older with newly diagnosed prostate cancer who have no evidence of distant metastatic disease and plan to get stereotactic body radiation therapy (SBRT) with or without androgen deprivation therapy (ADT). Design: Participants will be screened with: Medical history Physical exam Blood tests MRI Participants will have baseline MRI and PET/CT scans. For the MRI, they may get a contrast agent by IV injection. For the PET/CT scan, they will get an IV injection of 18FDCFPyL. About 1 to 2 hours later, they will get the PET/CT scan. During the scans, participants will lie on their back and remain still for 45 minutes to 1 hour. These scans will be repeated at different points during the study. Participants will get SBRT with or without ADT. Participants will complete questionnaires about their quality of life. Participants will be asked about any symptoms they are having. They will also be asked about medications they are using. They may have a physical exam. Participants will give blood and urine samples. They will give a tumor sample from a biopsy they have had in the past. After treatment, participants will have follow-up visits. These will occur 1 month after treatment, then every 3 months for a year, and then every 6 months for 1 more year.
Conditions Studied
Interventions
- DRUG 18F-DCFPyL
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2022-08-31 |
| Est. Completion | 2029-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05155046
The ClinicalTrials.gov registry entry for NCT05155046 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 96-participant average among 6 other Localized Prostate Cancer trials with a reported enrollment target (35% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Localized Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which 18F-DCFPyL is the first listed.
NCT05155046 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT05155046 about?
NCT05155046 is a clinical study titled "18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy". Background: Identifying medium- and high-risk prostate cancer early may allow for treatments to work. But identification can be hard. Researchers want to see if a radiotracer used during PET scans can help. Objective: To test how an imaging agent called 18F-DCFPyL detects response to standard pro...
What is the current status of trial NCT05155046?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2022-08-31. Estimated completion is 2029-12-31.
What conditions does trial NCT05155046 study?
This clinical trial studies the following conditions: Localized Prostate Cancer.
What interventions are being tested in trial NCT05155046?
The interventions under investigation include: 18F-DCFPyL (DRUG).
Who is sponsoring clinical trial NCT05155046?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05155046 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Localized Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
RECRUITING · Phase 2
-
Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.
ACTIVE NOT RECRUITING · Phase 2
-
WATER IV Prostate Cancer
RECRUITING · NA
-
PRCT002 PRostate Cancer Treatment With the AQUABEAM Robotic System
ACTIVE NOT RECRUITING · NA
-
PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs
ACTIVE NOT RECRUITING · NA
-
Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.